CHARACTERIZATION OF NOVEL HETROCYCLIC MOLECULES CONTAINING NITROGEN

Abstract

Nitrogen-containing heterocycles remain a cornerstone of medicinal chemistry because they combine structural diversity with tunable intermolecular interactions that govern receptor/enzyme recognition, solubility, and selectivity. Building on this rationale, the present work reports the design and synthesis of a focused series of pyrazole-linked thiazole hydrazones (P25–38), framed as lead-like scaffolds for multi-target bioactivity. The study’s strength lies in its emphasis on structure confirmation using complementary analytical platforms (FT-IR, ^1H/^13C-NMR, LC-MS, and CHNS elemental analysis), which collectively reduce ambiguity in scaffold assignment and support subsequent structure–activity interpretation. Representative spectral signatures: N–H stretching (~3320–3406 cm⁻¹), azomethine C=N bands (~1610–1615 cm⁻¹), diagnostic singlets for pyrazole-NH (~δ 11.8–11.9) and N=CH (~δ 8.1–8.2), and molecular ion consistency in MS; provide a coherent validation chain for the proposed hydrazone–thiazole–pyrazole framework. Biological screening indicates promising antimicrobial (and reported anti-inflammatory/anticancer) potential, with activity trends linked to electron-withdrawing aryl substituents. Notably, chloro/dichloro substitution patterns are repeatedly implicated as potency-enhancing features, suggesting that halogen-driven lipophilicity and electronic effects may improve target engagement and membrane permeability. The SAR discussion, while preliminary, points toward a practical optimisation pathway: systematic substituent modulation on the aryl rings to balance antibacterial efficacy with selectivity, alongside retaining hydrogen-donor motifs (e.g., C=N–NH) associated with antioxidant behaviour. Overall, the work positions these nitrogen-rich heterocycles as credible starting points for lead optimisation, but their translational value will ultimately depend on expanded bioassay panels, potency benchmarking, and mechanistic validation beyond single-point inhibition claims.